Connect with us

Industry

JuicyFields cannabis crowd growing movement challenges Canadian “green rush”

Published

on

JuicyFields: A hand holding a small cannabis plant.

JuicyFields crowd growing platform Vs. Canadian cannabis market: Overview of two medicinal cannabis hype cases with totally different approaches and outcomes.

Sponsored post

Despite a loud joyful boom that happened in Canada in 2019 when cannabis was moved to the legal side, the country has failed to drive the trend in a favourable direction. The so-called “green rush” has led production into overdrive.

As of today, the Canadian market has nothing else but low prices, poor quality and large quantities of cannabis produced annually, the large part of which remains in the shadow market. Like many independent researchers note, the legislation change made a lot of positive and negative impacts at the same time.

The greater number of licenses issued by the government had opened the doors of opportunities for entrepreneurs and yet, left them without quality standards, regulations and audit control. For comparison, there were 129 medical cannabis sales and cultivation licenses given out by Health Canada in October 2018 versus 540 licenses issued in 2020.

Generally, the boom has caused a race to the bottom from all aspects except medicinal prescriptions that still allow people to benefit from the cannabis treatment powers as long as the medicine itself is of decent quality.

JuicyField’s crowd growing concept

One can call overproduction without demand and quality control a hype without substance and this is exactly what JuicyFields counters in its niche.

Being the first company that introduced the crowd growing concept to the world, JuicyFields applies strict quality standards for cultivating medicinal cannabis at the licenced greenhouses around the world and by providing users of the eponymous platform to benefit after the plants are harvested and sold.

READ MORE  How Europe’s first medical cannabis tracking app could revolutionise care

Considering the location of headquarters in Europe as well as distribution of partners’ facilities in countries with cannabis-friendly legislation, JuicyFields keeps expanding and getting powerful companies and true agricultural, legal, sales and scientific experts in all spheres aboard.

Partnering allows JuicyField’s operations to cover more than 150,000 sqm of land. Marijuana harvested totalled in excess of 37 tonnes of medicinal marijuana in the first half of 2021 alone.

According to founder and CEO Alan Ganse the growth has only begun and the company’s, “major goal is to be listed in the TOP 5 cannabis producers by 2025 along with such giants as Curaleaf, Trulieve Cannabis, Canopy Growth and Green Thumb Industry. We aim to produce not less than 379 tonnes of cannabis and become the number one brand among psychoactive medical and recreational cannabis products.”

JuicyFields: a hand with a blue glove on holding a bottle of Cannabs oil in a pipette.

The Canadian case

JuicyFields has already proved to its supporters, partners and distributors an ability to overcome obstacles, maintain the strictest GMP (Good manufacturing practices) and EU GMP standards within the industry in order to provide quality end-customer products to the market.

Looking back to the Canadian case, it becomes evident that the country couldn’t cope with the “green rush” and this example can be used as a guide of what any large cannabis movement should avoid and be careful with.

Read more: JuicyFields aims to be one of the top five producers of medical cannabis

Industry

Rapper Lil’ Kim announces new cannabis brand ‘aphrodisiac’

The New York rapper becomes the latest celebrity to launch their own cannabis collection which is due in 2022.

Published

on

Image: Instagram/lilkimthequeenbee

The singer has announced the launch of her own cannabis brand, Aphrodisiac which is being produced in partnership with Superbad inc.

Lil Kim’s new products will be available across California in 2022, although there is no official launch date announced.

The brand is being produced in collaboration with the innovative cannabis brand, Superbad inc. Superbad was established in 2020 combining cutting edge technology and sleek design for cannabis consumers. They currently have seven acres of indoor grow and a “state-of-the-art facility” employing over 200 people.

Kimberly Denise Jones who goes by her stage name, Lil’ Kim has been working on the brand for two years. She has also partnered with the brand CampNova, which offer vertically integrated marketing and a distribution platform.

The rapper wants the cannabis line to reflect her personal style and says she has personally tested her own products. The collection is tailored to Lil’ Kim’s own preference in genetics and strains.

Lil' Kim: A banner advert for Always Pure Organics

Lil’ Kim collection

There are plans to expand the range to other legal states such as Michigan, New Jersey and New York. Originally from New York, Lil’ Kim hopes to be able to release the collection in her home state.

In an interview with Forbes magazine, she said: “I’ve actually been working on this for about two and a half to three years. This is something that didn’t just come overnight. It’s something I’ve always wanted to do.”

Lil’ Kim is the latest celebrity to enter the cannabis space with her own collection. Earlier this year, Justin Bieber announced he would be releasing a collection of pre-rolls called Peaches with premium brand Palms. The products are currently available in California, Nevada, Massachusetts and Florida.

READ MORE  A growing market for new cannabinoids

In a press release, he stated: “I’m a fan of Palms and what they are doing by making cannabis approachable and helping to destigmatise it — especially for the many people who find it helpful for their mental health.”

 

Image rights: Lil’ Kim

Continue Reading

Industry

Always Pure Organics: A day in the life with Chikako Yoshida

Regional Director of Asia, Chikako Yoshida, gives us a glimpse of her typical workday and discusses working in cannabis.

Published

on

Always Pure Organics: A man and a woman working on a laptop.

Chikako Yoshida, regional director of Asia for Always Pure Organics shares her experience of working in the cannabis industry.

Always Pure Organics is excited to give you a glimpse behind the curtain once again.

Join us for our latest episode of a Day in the Life, in which regional director of Asia, Chikako Yoshida discusses her experience working for Always Pure Organics and in the cannabis industry.

Always Pure Organics: A woman walking down a white and yellow hallway

In this episode, we follow our Regional Director of Asia, Chikako Yoshida, as she takes us through her typical workday. Having previously worked in counterterrorism for the United Nations, Chikako joined the APO team in May 2020. Chikako has such an interesting story to tell, we’re honoured to have her on the team as she embodies our mission to cultivate cannabis acceptance and accessibility worldwide. 

Chikako Yoshida said: “Upon learning about the power of cannabis and seeing the high potential growth of Always Pure Organics, I decided to change career from preventing illicit drugs to promoting cannabis to help people in need. I feel that by joining APO, I can help fulfil my life’s mission to support children and their families who fight against illness and sickness by providing them with cannabis products.”

Read more: Always Pure Organics achieves COSMO standard

Always Pure Organics: A banner explaining how the collaborative post works

READ MORE  "I'm forced to choose between life-changing medication or paying the bills"
Continue Reading

Epilepsy

CBGA may be ‘more potent’ than CBD against seizures in Dravet syndrome

Dr Lyndsey Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.

Published

on

Seizure: A row of test tubes containing CBGA oil with a doctors white gloved hand holding one up to the light

Scientists say they have found the ‘Mother of all cannabinoids’ which may help to reduce seizures in Dravet syndrome.

A new study on mice from the University of Sydney found that three acidic cannabinoids found in cannabis reduced seizures in Dravet syndrome, an intractable form of childhood epilepsy.

The three cannabinoids are cannabigerolic acid (CBGA), cannabidivarinic acid (CBDVA), cannabigerovarinic acid (CBGVA). All three but CBGA in particular “may contribute to the effects of cannabis-based products in childhood epilepsy” noted the researchers and were found to potentially have ‘anticonvulsant properties.”

The study marks the first time that three acidic cannabinoids were found to potentially help reduce seizures for Dravet syndrome.

Speaking with Cannabis Health News, the lead author of the study, Dr Lyndsey Anderson, said: “We found that CBGA exhibited both anticonvulsant and pro-convulsant effects. CBGA was more potent than CBD against febrile seizures in a mouse model of Dravet syndrome. We also found that a combination of CBGA and clobazam was more effective than either treatment alone. Additionally, we found that CBGA was anticonvulsant in the maximal electroshock acute seizure model, a model for generalized tonic-clonic seizures.”

She added: “CBGA did, however, present some proconvulsant effects. The frequency of spontaneous seizures in the mouse model of Dravet syndrome was increased with a high dose of CBGA. Also, CBGA was proconvulsant in the 6-Hz acute seizure model, a model of focal, psychomotor seizures.”

Although CBGA shows promise, Dr Anderson also stressed that it needs more research before it can replace CBD. She cautioned that Dravet syndrome patients may still need to proceed with caution.

READ MORE  Ireland's medical cannabis exclusions will lead to 'life-threatening' crisis

“Artisanal cannabis-based products are believed to reduce seizures in Dravet syndrome patients,” she said. “As these oils contain rare cannabinoids like CBGA, it is possible CBGA then contributes to the anticonvulsant effects of these artisanal cannabis oils. However, there were proconvulsant effects observed with CBGA, suggesting that Dravet syndrome patients may need to proceed with caution. The proconvulsant liability of CBGA would need to be addressed before it replaced CBD as an anticonvulsant.”

What is CBGA?

Sometimes referred to as ‘the mother of all cannabinoids,’ CBGA is the precursor molecule to many different cannabinioids including CBD and THC. It is thought to help some diseases such as colon cancer, metabolic disease and cardiovascular disease. It is a non-intoxicating cannabinoid much like CBD.

Dr Anderson explains that more research is needed to explain how the three cannabinoids work together.

“We don’t know how they work together yet,” she said. “We found that CBGA, CBDVA and CBGVA were all individually anticonvulsant against thermally induced seizures in the mouse model of Dravet syndrome. We did not investigate whether a combination of these three cannabinoids would result in a greater anticonvulsant effect than either cannabinoid alone. Future work will definitely explore this possibility.”  

CBGA future research

This isn’t the end of the research into CBGA for Dravet Syndrome. Dr Anderson said there is more to explore when it comes to creating more treatment options for Dravet syndrome.

 

She said: “Next on the horizon for this research is to explore whether the anticonvulsant properties of CBDVA and CBGVA translate to other seizure types including spontaneous seizures in the mouse model of Dravet syndrome. Additionally, we have extensively interrogated the anticonvulsant potential of individual cannabinoids and identified ten with anticonvulsant properties.”

READ MORE  APO's CBD products star on Japanese TV

 

“We are now interested in investigating what happens when we combine these anticonvulsant properties. It remains an open possibility that greater anticonvulsant effects are achieved when the cannabinoids are administered in combination.”

The study was recently published in the British Journal of Pharmacology (DOI: 10.1111/bph.15661)

Continue Reading

Trending

Cannabis Health is a journalist-led news site. Any views expressed by interviewees or commentators do not reflect our own. All content on this site is intended for educational purposes, please seek professional medical advice if you are concerned about any of the issues raised.

Copyright © 2021 H&W Media Ltd.